Printer Friendly

STERLING WINTHROP CHAIRMAN/CEO LOUIS P. MATTIS HONORED AS PHARMACEUTICAL EXECUTIVE OF THE YEAR BY PHARMACEUTICAL EXECUTIVE MAGAZINE

 ORLANDO, Fla., Nov. 1 /PRNewswire/ -- Louis P. Mattis, chairman and CEO of Sterling Winthrop Inc., was awarded the first Pharmaceutical Executive of the Year Award at the Pharmaceutical Executive Conference '93, sponsored by Pharmaceutical Executive magazine. The award was presented to Mattis in recognition of his vision and leadership which has catapulted Sterling Winthrop into the top tier of the industry and resulted in leading edge initiatives that strengthened the company's entrance "into new and emerging geographic and therapeutic markets."
 In addressing the more than 200 industry executives here, Mattis remarked, "Sterling Winthrop people around the world have spent the past five years re-inventing our company. This process has taken us into new markets, new therapeutic areas and into new ways of doing business on a global scale."
 Since 1987, Sterling Winthrop has undertaken a number of initiatives to revitalize the company, including restructuring into two global lines of business (pharmaceuticals and consumer health products), creating a unique transnational alliance with the French pharmaceutical company Elf Sanofi, and aligning the efforts of its 13,000 people around the world with an innovative, participative management process.
 "This award recognizes the accomplishments and progress of the people of Sterling Winthrop," said Mattis. "For Sterling Winthrop, thinking differently and finding new ways of doing things are part of our culture. These are the reasons we have been able to make significant progress against our mission: creating distinctive, cost- effective solutions for the needs of mankind in pharmaceuticals and consumer health products."
 In accepting the award, Mattis described Sterling Winthrop's continued emergence among the leaders in the industry. Today, together with its alliance partner, Elf Sanofi, the company ranks in the top 20, is well-balanced between pharmaceuticals and consumer health products, and has research and development spending in excess of one-half billion dollars focused on innovative treatments and cures for such diseases as cancer, heart disease, disorders of the central nervous system and chronic inflammatory disease.
 Mattis challenged the industry to recognize the dramatic change in the health care environment and to better communicate the value of pharmaceuticals to its publics around the world.
 "Pharmaceuticals save millions of lives. Pharmaceuticals improve the quality of life for millions. And the research and development based pharmaceuticals industry offers the only true hope for future major advances in treatment and cures for the major unmet medical needs of the people of the world," said Mattis.
 Sterling Winthrop Inc., a subsidiary of Eastman Kodak Company (NYSE; EK), is a worldwide developer, manufacturer and marketer of pharmaceuticals and consumer health products.
 -0- 11/1/93
 /CONTACT: Diane C. Iselin, 212-907-2341, or Carol J. Perlman, 212-907-2724, both of Sterling Winthrop/
 (EK) CO: Sterling Winthrop; Eastman Kodak Company ST: New York IN: MTC SU:


LG-TW -- NY066 -- 9235 11/01/93 14:42 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1993
Words:462
Previous Article:IT WAS MRS. WHITE IN THE HALL WITH THE WRENCH
Next Article:FIRST USA COMPLETES PREVIOUSLY ANNOUNCED ACQUISITION OF MAGROUP, INC.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters